ClinicalTrials.gg
RecruitingNCT07310095Updated Nov 3, 2026

A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)

A Phase 4 interventional study of Guselkumab (GUS) in Crohn Disease, sponsored by Xian-Janssen Pharmaceutical Ltd.. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing guselkumab in Crohn Disease — 6 open to participants now, 11 under way, 7 of them phase 3. guselkumab · Crohn Disease.

Planned enrollment
10th of 13
78 · median 196
Started
2025
the only one that year
Phase 4
3 of 13
3 open now
Primary completion
2027-09
later than 6 of 10 live
Registered
10th of 13
by date
Lead sponsor
1 of 13
Xian-Janssen Pharmaceutical Ltd.

Among the 13 studies testing guselkumab in Crohn Disease, this one is the 10th largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 4, reaches primary completion later than 6 of the 10 other live ones, and was the 10th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 13 studies testing guselkumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing guselkumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.

03

Conditions studied

  • Crohn Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a confirmed diagnosis of Crohn's disease (CD)
  • Diagnosed with active CD, as defined by baseline Crohn's Disease Activity Index (CDAI) score greater than or equal to (>=) 220
  • Participants had received the ustekinumab (UST) induction phase and received maintenance therapy via subcutaneous (SC) injection every 8 weeks or every 12 weeks
  • Initially responded to UST induction therapy and then lose response to UST
  • During the screening period, participants are receiving UST treatment as the biologic or second line biologic

Exclusion criteria

Exclusion Criteria:

  • Received UST dose optimization or multiple intravenous therapy in maintenance phase
  • Participants with CD requiring urgent surgical or endoscopic intervention, or requiring elective surgery within 2 months
  • Is currently enrolled in an interventional clinical study
  • Complications of CD, such as symptomatic strictures or stenoses, short gut syndrome
  • Have a current or be suspected to have an abscess
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Guselkumab Treatment

    Participants will receive Guselkumab intravenously (IV) every 4 weeks during the induction phase, followed by subcutaneous (SC) administration of Guselkumab every 4 weeks from Week 12 through Week 44 as maintenance therapy.

    Drug: Guselkumab (GUS)

Interventions

  • Guselkumab will be administered intravenously or by subcutaneous injection.

    Also known as: TREMFYA

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Remission At Week 48

    Clinical remission is defined as less than (\<) 150-point reduction in Crohn's Disease Activity Index (CDAI) score. The CDAI is a validated multi-item measure of severity of illness derived as a weighted sum of 8 different Crohn's disease-related variables. The CDAI score was assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s), and/or opiates, and general well-being. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities.

    Time frame: At Week 48

Secondary outcomes

  1. Percentage of Participants Achieving Clinical Response At Weeks 12, 24 and 48

    Clinical response is defined as greater than or equal to (\>=) 100-point reduction from baseline in CDAI score. The CDAI is a validated multi-item measure of severity of illness derived as a weighted sum of 8 different Crohn's disease-related variables. The CDAI score was assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s), and/or opiates, and general well-being. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities.

    Time frame: At Weeks 12, 24 and 48

  2. Percentage of Participants Achieving Clinical Remission At Weeks 12 and 24

    Clinical remission is defined as \< 150-point reduction in CDAI score. The CDAI is a validated multi-item measure of severity of illness derived as a weighted sum of 8 different Crohn's disease-related variables. The CDAI score was assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s), and/or opiates, and general well-being. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities.

    Time frame: At Weeks 12 and 24

  3. Percentage of Participants Achieving Endoscopic Response

    Endoscopic response is defined as \>= 50% improvement from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) score. The SES-CD is based on the evaluation of 4 variables: (ulcers - scored according to size, proportion of the surface covered by ulcers according to extent, proportion of affected surface with any other lesions according to extent, stenosis \[single or multiple, and whether the colonoscopy could pass through the narrow lumen\]), each considered in 5 segments of the bowel (the ileum, ascending colon, transverse colon, descending colon, and rectum). An overall total SES-CD score is derived from the sum of all the component scores and can range from 0 to 60. Higher scores indicating severe disease.

    Time frame: At Weeks 24 and 48

  4. Percentage of Participants Achieving Endoscopic Remission

    Endoscopic remission is defined as SES-CD less than or equal to (\<=) 2 in any individual component. The SES-CD is based on the evaluation of 4 variables: (ulcers - scored according to size, proportion of the surface covered by ulcers according to extent, proportion of affected surface with any other lesions according to extent, stenosis \[single or multiple, and whether the colonoscopy could pass through the narrow lumen\]), each considered in 5 segments of the bowel (the ileum, ascending colon, transverse colon, descending colon, and rectum). An overall total SES-CD score is derived from the sum of all the component scores and can range from 0 to 60. Higher scores indicating severe disease.

    Time frame: At Weeks 24 and 48

  5. Baseline Characteristics of Participants With Endoscopic Remission: Age

    Baseline characteristics of participants (age) with endoscopic remission will be reported.

    Time frame: Baseline

  6. Baseline Characteristics of Participants With Endoscopic Remission: Sex

    Baseline characteristics of participants (sex) with endoscopic remission will be reported.

    Time frame: Baseline

  7. Baseline Characteristics of Participants With Endoscopic Remission: Height

    Baseline characteristics of participants (height) with endoscopic remission will be reported.

    Time frame: Baseline

  8. Baseline Characteristics of Participants With Endoscopic Remission: Weight

    Baseline characteristics of participants (weight) with endoscopic remission will be reported.

    Time frame: Baseline

  9. Baseline Characteristics of Participants With Endoscopic Remission: History of Advanced Treatment, Concomitant Medications

    Baseline characteristics of participants (history of advanced treatment, concomitant medications) with endoscopic remission will be reported.

    Time frame: Baseline

  10. Baseline Characteristics of Participants With Endoscopic Remission: Comorbidities

    Baseline characteristics of participants (comorbidities) with endoscopic remission will be reported.

    Time frame: Baseline

  11. Baseline Characteristics of Participants With Endoscopic Remission: Surgeries and Procedures

    Baseline characteristics of participants (surgeries and procedures such as apheresis) with endoscopic remission will be reported.

    Time frame: Baseline

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 20 months after the start.

Of 70 phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 68. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Dec 30, 2025
Primary completionEst.
Sep 15, 2027
CompletionEst.
Nov 15, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07310095
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Dec 30, 2025
Primary completion
Sep 15, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Xi'an Janssen Pharmaceutical Clinical Trial
study director · Xi'an Janssen Pharmaceutical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion